Persistent glucocorticoid resistance in systemic lupus erythematosus patients during clinical remission
, “Persistent glucocorticoid resistance in systemic lupus erythematosus patients during clinical remission”, vol. 12, pp. 2010-2019, 2013.
Glucocorticoids (GCs) are key drugs in the treatment of systemic lupus erythematosus (SLE). GC dose reduction during remission is related to disease activity, GC dose used, length of treatment, and individual GC sensitivity. We compared GC receptor α (GRα) isoform and nuclear factor kappaB (NF-κB) messenger RNA quantitation and in vivo GC sensitivity between SLE patients during remission and healthy controls. We performed a cross-sectional study of 19 women aged 22-49 years, including 9 SLE patients in clinical remission taking ≤5 mg prednisone and 10 matched controls.
